Strategies for the purification of high titre, high volume mammalian cell culture batches
|
|
- Justina Lyons
- 6 years ago
- Views:
Transcription
1 Strategies for the purification of high titre, high volume mammalian cell culture batches Martin P. Smith. LONZA Biologics plc, 228 Bath Road, Slough, SL1 4DX. Presented at, Recovery & Purification. BioProcess International European Conference and Exhibition. Berlin, April 2005.
2 Overview Review of Fermentation process productivity increases Current status Challenges presented by high titre, high volume batches Strategies available for dealing with high-titre, high-volume batches Opportunities within current downstream processing technologies Chromatography Buffer supply Ultrafiltration Importance of timely process development Simple tools & methods for process development and scale-up 15/04/2005 / 2
3 LONZA Biologics manufacturing capacity LONZA currently operates monoclonal antibody facilities in both the US and UK UK Manufacturing-focused on rapid supply of clinical phase material Various disposable units (Wave ) 2x2000L ALF 2x200L ALF Additional capacity planning exercise underway US Manufacturing-focused on large-scale late phase & in-market supply 2x5000L ALF 1x2000L ALF 2x1500L perfusion (dedicated) 3x20,000L STR growing to 4 in /04/2005 / 3
4 Biopharmaceutical Production Challenges Increased demand for cgmp manufacturing capacity at all scales. Increase in product approvals and marketing extensions driving a demand for large scale capacity (>5000L reactor volume) Strong demand for small scale capacity driven by full customer pipelines and need for early phase toxicology & clinical study material. Cell Line Construction cgmp Cell Banking Scale-Up & Process Pilot Prod. Development cgmp Manufacture Growing political and ethical pressures to control and reduce drug development time-to-market and production costs. 15/04/2005 / 4
5 Advances in Mammalian Cell Culture Process Productivity Product Accumulation (mg/l) Iteration 1 (22H11) Iteration 2 (22H11) Iteration 2 (LB01) Iteration 3 (LB01) Iteration 4 (LB01) Iteration 5 (LB01) Iteration 5 (CY01) Fermentation Time (days) Fermentation productivity is rising RAPIDLY. Advances in cell culture realising higher titres Already experiencing 4-5g/L batches after 14days in cgmp reactors 15/04/2005 / 5
6 Current Capacity Crunch Much of today s production capacity for in-market supply designed for low to modest productivities of monoclonal antibodies Resulted in requirement for multiple large volume reactors (4-6 x 12-20kL) for single purification trains. In-house BioPharma capacity can be optimised for specific medium to low risk products Contract Manufacturing capacity must remain reflective of wider industry status to capture current and near term business Rate of technology development in mammalian expression outpacing design-and-build timelines for new facilities Industry requires low risk, low capital and immediate solutions to purifying high productivity batches across all scales. 15/04/2005 / 6
7 Identifying bottlenecks in downstream processing Situation for CMO s is more complicated than single product facilities Business risk managed through large customer base Each product differs widely despite generic/platform technologies Fermentation productivities column capacities, number of column steps Differing degrees of process intensification Increasing titres poses significant challenges for: Throughput (speed of purification) Economics (Batch cost, cost of goods) 15/04/2005 / 7
8 Strategies to alleviate downstream processing bottlenecks 1. Invest in development of novel technologies Membrane Adsorbers (PnA capture and contaminant removal) Mimetic ligands Monolithic chromatography supports UV for virus inactivation 2. Invest in development of conventional technologies Centrifugation 2 phase separations Solvent extraction Precipitation Crystallisation 15/04/2005 / 8
9 Factors complicating selection of strategy 5g/L titres are here now! Novel technology and re-development of conventional technologies may not help in the near term Both involve significant investment of capital to refit existing facilities Need to sell technology improvements Internally across company Externally to clients Technology solutions must be scalable and generic 15/04/2005 / 9
10 Further Strategies to alleviate downstream processing bottlenecks 3. Maximise utilisation of existing assets. Process Optimisation Downstream Yield Improvement Programs Process Intensification Reduce processing time Eliminate non-processing time Reduce start-up and turn around/change over times 4. Drive process excellence across business LEAN/Six Sigma/Quality systems 15/04/2005 / 10
11 Typical Development Program Construct expression vector Construct Cell Line Develop Manufacturing Process Non GMP Pilot Run GMP Production Material Supply Typical Quantities Cell culture supernatants Protein A purified product Research grade fully purified product Material for toxicology studies, reference standard, stability studies 10-50mls 10-50mgs 0.1-1g g Clinical Trial Supply 0.1kg to multi-kgs Speed to Clinic for Early Phase material ensured through use of generic processes Fast Track Downstream development characterised by aggressive timelines 15/04/2005 / 11
12 Focus of presentation Bottlenecks and Production Economics change markedly as a function of scale. Key bottlenecks and areas for cost/throughput optimisation: Protein A Capture Buffer Supply Ultrafiltration Optimisation 15/04/2005 / 12
13 Effect of fermentation titre on intermediate process volumes Example of 2000L reactor titre increase. For same purification process: 1g/L Chromatography elution tank volume constraints Ultrafiltration tank volume capacity 2500 Virus filtration throughput constraints Increased demand for buffers Process Volume vs Concentration /04/2005 / 13 Harvest Process Vol (L) CCS PnA Eluate VI Eluate UF 1 Product Q FT UF 2 Product VRF Product SP Product UF 3 Product Process conc (g/l) L g/l Process Volume vs Concentration Harvest Process Vol (L) CCS PnA Eluate VI Eluate UF 1 Product Q FT UF 2 Product VRF Product SP Product UF 3 Product Process conc (g/l) L g/l 5g/L
14 Process Development Case Study 1 Reducing Buffer loading during downstream processing 2000L reactor titre increase. Total Buffer Demand (L) 40,000 35,000 30,000 25,000 20,000 15,000 10,000 5,000 0 Effect of Fermentation Titre on Buffer Demand Fermentation Titre (g/l) % of buffer Demand is derived from Protein A step 15/04/2005 / 14
15 Large Scale Build Out Facility, Buffer Hold-Upper Level 15/04/2005 / 15
16 Buffer Concentrates and In-Line Dilution Possible to minimise Buffer Make-up and Hold requirements through in-line dilution Example: Protein A Equilibration, Post Load Wash Buffer 50mM Glycine Glycinate, 250mM Sodium Chloride, ph 8.0 Cl - H 3 N + COOH C H - COO pka =2.35 pka = H 3 N + 2 C H H 2 N COO - Na + C H H Glycine Hydrochloride (AA +1 ) H Isoelectric Glycine (free base) (AA 0 ) Implementing in-line dilution requires In-depth understand of buffer chemistry Solubility and stability of buffer concentrates Effect of temperature on ph and ms/cm Appropriate equipment for in-line dilution H Sodium Glycinate (AA -1 ) 15/04/2005 / 16
17 Protein A Equilibration Buffer Chemistry Effect of temperature on atstrength buffer ph & ms/cm Static dilution of buffer concentrates ph (-) Temperature ( C) Conductivity (ms/cm) ph (-) Concentrate Strength (-) Conductivity (ms/cm) Establish process tolerance for ph and ms/cm (as wide as possible) Check ability to control concentrate and WFI temperature Ensure buffer concentrate is soluble at required strength Check Salt Strength at ph for compatibility with MOC s 15/04/2005 / 17
18 Demonstrating potential for in-line dilution % B Volumetric Flowrate (L/h) 5x Dilution 10x Dilution 15/04/2005 / 18
19 10x Concentrate dilution at 20L/h ms/cm CIR101 CIR102 AIR121pH FIR141 TIR101 SetMark ph % B x Dilution 10x Dilution Water rinse 1x baseline 10x_concentrate Feedback enabled Volumetric Flowrate (L/h) min x concentrate: 500mM Gly-Gly, 2500mM NaCl, 8.03pH, ms/cm Controller set point = 15%B for 10x dilution to 25.1mS/cm 15/04/2005 / 19
20 10x Concentrate dilution at 120L/h ms/cm CIR101 CIR102 AIR121pH FIR141 TIR101 SetMark ph % B x Dilution 10x Dilution Water rinse 1x baseline 10x_concentrate Feedback enabled Volumetric Flowrate (L/h) min Feedback enabled min /04/2005 / 20
21 Importance of in-line dilution for addressing demands of high titre batches. Careful selection of buffers during early phase development can alleviate serious headaches at scale later Select buffers (especially equilibration/wash) that can be prepared in concentrate form Design capability for in-line dilution into chromatography and ultrafiltration rigs Possible to obtain a 30-40% reduction in total buffer prep and hold requirements for equilibration buffers alone 15/04/2005 / 21
22 Process Development Case Study 2 Throughput optimisation-protein A capture Recent advances in Protein A matrix design High throughput matrices High capacity matrices Alkali stable options Explore relationship between titre increase and matrix selection Examine impact of column diameter on process design and operation 15/04/2005 / 22
23 Effect of fermentation titre on column capacity PnA Sepharose, 0.5g/L 10x increase in fermentation titre PnA Sepharose, 5g/L 83% increase in binding capacity under identical conditions Breakthrough (C/Co) % IgG loaded (mg/ml.matrix) Despite increased binding capacity, compressibility limits attainable throughput and scale-up potential Pressure Drop (psi) Linear velocity (cm/h) Column Diameter 1.6cm 2.6cm 5.0cm 10cm 20cm 28cm 40cm 140cm 15/04/2005 / 23
24 Addressing chromatographic throughput MabSelect, 0.5g/L MabSelect, 5g/L Incompressible matrices offer benefit of higher throughput. Essential for high volume fermenters Breakthrough (C/Co) % Breakthrough curves generated at 450cm/h (3x faster than Sepharose maximum ) 23% increase in binding capacity at 5% C/Co under identical conditions IgG loaded (mg/ml.matrix) 15/04/2005 / 24
25 Importance of matrix selection on process throughput at different titres 2000L Reactor 0.5g/L Titre 5g/L Titre Rmp Protein A Sepharose FF MabSelect Conclusion High throughput matrices can deliver 50% improvement in throughput at high fermentation titres 15/04/2005 / 25
26 Influence of column diameter on batch and campaign costs. 2000L reactor at 5g/L MabSelect for initial capture Small PnA Column Large PnA Column No difference in campaign cost over 15 batches 15/04/2005 / 26
27 Factors to consider when selecting a column diameter Range of fermentation titres across all products in portfolio (Flexibility) A wide range in titre drives higher utilisation of narrower column diameters Campaign length (number of batches) longer campaigns may favour large diameter columns Risk Bioburden contamination, operating close to re-use limits Capital equipment requirements more chromatography skids, larger elution tanks) Facility design, operation, logistics floor space-processing/storage, packing-unpacking 15/04/2005 / 27
28 Adressing capacity challenges with larger columns Small diameter columns Large diameter columns Lower capital costs Columns and skids Lower one-off batch costs Higher capital costs Columns (stainless?) Skids Increased flexibility across range of titres Extremely high first batch and replacement PnA costs Potential issues with high utilisation rates of equipment Maintenance Column Re-packing Large elution volumes per cycle High exposure to risk through contamination (e.g. bio-burden) or other process failure 15/04/2005 / 28
29 Stay abreast of latest vendor offerings Amersham Matrix launches Protein A Seph 4FF 1996 rprotein A Seph 4FF 2000 rmp Protein A Seph 4FF 2001 MabSelect 2005.MabSelect SuRe, Xtra Immunoglobulin binding domains Ss E D A B C XM Gly29Ala mutation Z domain 15/04/2005 / 29
30 Higher through, higher capacity, alkali stability rmppna Seph 4 FF Mabselect Prototype SuRe Rmp Protein A 4 FF XK16, 15cm Ho, 150cm/h, 6min RT 5% C/Co = 26g/L Op.DBC = 20.8g/L Breakthrough (C/Co) % Antibody Loaded (mg/ml) MabSelect TC5, 20cm Ho, 500cm/h, 2.4min RT 5% C/Co = 19g/L Op.DBC = 15.2/L MabSelect SuRe TC5, 20cm Ho, 500cm/h, 2.4min RT 5% C/Co = 26g/L Op.DBC = 20.8g/L 15/04/2005 / 30
31 Strategies for Chromatography Process Development Ensure process development teams understand manufacturing requirements: High throughput per batch? Low batch costs? Operate closer to 1% Breakthrough to minimise cycling requirements Operate as close to matrix throughput limits as manufacturing capabilities permit (minimise residence time) Employ latest matrix technologies Ensure processes have detailed cost models to justify/defend process decisions 15/04/2005 / 31
32 Individual Reactor Volume established at 20,000L LONZA Biologics LSBO Facility 3x20,000L Reactors Increasing to 4 Reactors in 2006 Purified through a Single Purification train 15/04/2005 / 32
33 Do ultra-large columns adequately meet high titre challenge? LSBO Facility designed to handle high-titre batches Protein A Capture in either a 1.4 or 2.0 m diameter Chromatography column. Chromatographic capture of 20,000L at 5g/L feasible given facility design basis 15/04/2005 / 33
34 Process Development Case Study 3 Ultrafiltration Optimisation Early Phase fast track development may not allow sufficient time to optimise UF operations Diafiltration conditions may be selected based on Prior experience with antibody class/pi Prior experience with particular cassette type/vendor Manufacturing equipment capabilities Antibody stability UF optimisation can substantially improve purification process performance 15/04/2005 / 34
35 Ultrafiltration Optimisation Flux - J ctmp High Q Med Q Low Q TMP Bulk Flow (C b ) Crossflow Flux - J Boundary Layer Gel Layer (C g ) Membrane C b Increasing Concentration C g C df = C e g ln C C g 15/04/2005 / 35
36 Results from an Ultrafiltration optimisation Membrane Area = 40 m2 Initial Volume = 7,300 L Initial concentration = 5.24 g/l, concentrated to membrane Cg Membrane Un-Optimised Optimised Gel Concentration (Cg) (g.l -1 ) Optimum Process Conc (Cg/e) (g.l -1 ) Flux at Cg/e (L.m -2.h -1 ) Diafiltration Volume (L) 2,332 1,443 5 x Diafiltration Volume (L) 11,660 7,215 Concentration Time (h) 2 h 32 min 1 h 22 min Diafiltration Time (h) 9h 22 min 3h 2 min Total Process Time (h) 11 h 54 min 4 h 24 min Un-optimised Pin = 20 psig Pout = 5 psig Cross flow = 1x Optimised Pin = 35 psig Pout = 12 psig Cross flow = 1.33x 15/04/2005 / 36
37 Ultrafiltration Optimisation Influence of Cassette type and vendor Total Process Time (h) Omega Biomax Hydrosart Alpha 5 x DF Volume Product Concentration at DF (g.l -1 ) 20k 18k 16k 14k 12k 10k 8k 6k 4k 2k Diafiltrate Volume (L) Model: 40kg batch Membrane Area = 40 m2 Initial Volume = 7,300 L Initial concentration = 5.24 g/l, concentrated to Cg, 5 diavolumes. Key Polyethersulfone Vendor 1 Polyethersulfone Vendor 2 Regen. Cellulose Vendor 2 Regen. Cellulose Vendor 3 Wide variation in optimised performance across different UF cassettes, especially at extremities of protein concentration 15/04/2005 / 37
38 Large Scale Ultrafiltration-80m 2 capacity 15/04/2005 / 38
39 Ultrafiltration Optimisation Optimisation of UF operations can deliver reduced processing times and considerable reduction in buffer volumes Simple ultrafiltration optimisation can be performed in a single day with tremendous benefits Avoid mid-range operating conditions-lead to un-optimised processes Product stability at elevated concentrations should be assessed with appropriate stability studies 15/04/2005 / 39
40 Summary Maximise utilisation of existing assets for as long as possible Optimise performance of unit operations early in development life cycle Employ high throughput chromatography matrices Select buffers with in-line dilution in mind Strive for purification at elevated protein concentration wherever possible However above strategy may have only a limited lifespan Parallel track with investment into novel and conventional technologies 15/04/2005 / 40
The Influence of Scale of Operation on Purification Process Design
The Influence of Scale of Operation on Purification Process Design Jim Davies, Martin Smith, Julian Bonnerjea Dr Jim Davies Biochemical Engineer Lonza Biologics Slough UK Introduction Product Requirement
More informationA CMO s View on Platform Technologies
Pharma&Biotech A CMO s View on Platform Technologies A3P BioProduction 2013 BioPurification, Lyon, France Louise Elise-marie Ingram/ Seng Lonza /, Basel Biologics / 10. Mai / 182012 Jun 13 Disclaimer Certain
More informationBioprocessing Challenges: High-Titer Mammalian-Based Cell Systems. Elements influencing the way Biologics may be manufactured /supplied in the future
Bioprocessing Challenges: High-Titer Mammalian-Based Cell Systems Jonathan Romero CMC Leadership, Technical Development Pharmaceutical Operations & Technology 2015 ISPE PRODUCT SHOW Business Drivers Elements
More informationUse of Fluidised bed chromatography for plasma fractionation. Karl McCann*, John Wu, Peter Gomme & Joseph Bertolini
Use of Fluidised bed chromatography for plasma fractionation Karl McCann*, John Wu, Peter Gomme & Joseph Bertolini Plasma Fractionation Industry Mature with well established processes Revenue growth -
More informationFuture Perspectives of Antibody Manufacturing
BioProduction 2005 Amsterdam Future Perspectives of Antibody Manufacturing John Birch Lonza Biologics Monoclonal Antibodies A Success Story Fastest growing segment of the pharmaceutical market Sales forecast
More informationMabSelect SuRe. GE Healthcare. Alkali-stabilized protein A-derived medium for capture of monoclonal antibodies. High stability in alkaline conditions
GE Healthcare Data File 11-11-65 AB Affinity chromatography MabSelect SuRe Alkali-stabilized protein A-derived medium for capture of monoclonal antibodies MabSelect SuRe (Superior Resistance) is a member
More informationCapture of mouse monoclonal antibodies
Capture of mouse monoclonal antibodies by cation exchange chromatography Life Science Products Processing Capture of mouse monoclonal antibodies from cell culture supernatant by cation exchange chromatography
More informationThe Braine BioPilot An Integral Part of Bioprocess Development for Cell Culture- Based Biologics
The Braine BioPilot An Integral Part of Bioprocess Development for Cell Culture- Based Biologics Visit of Alabama Biotech Oct 2014 Alain BERNARD Vice President GPS, UCB Technical Operations Tech Ops BioTech
More informationApplication Note. Rapid optimisation and development of an automated two-step purification procedure for monoclonal IgG antibodies.
Rapid optimisation and development of an automated two-step purification procedure for monoclonal IgG antibodies Application Note ÄKTAFPLC Convenient and rapid standard purification protocol for monoclonal
More informationA novel approach to Protein A capture chromatography to help decrease cost of clinical manufacturing and reduce supply chain risk
PRODUCT BULLETIN POROS MabCapture A resins A novel approach to Protein A capture chromatography to help decrease cost of clinical manufacturing and reduce supply chain risk Introduction As cell culture
More informationTable 1, Performance characteristics of Cellufine SPA-HC
SPA-HC An affinity chromatography resin designed for the isolation of immunoglobulins, including monoclonal antibodies (mab) from complex matrices, such as cell culture supernatant and serum/plasma. Cellufine
More informationApplication of Disposable Technologies in Biopharmaceutical Manufacturing
BMD Summit, Disposables for Biopharm Production 13th December 2005 Reston, VA, USA Application of Disposable Technologies in Biopharmaceutical Manufacturing Martin Wrankmore, Continuous Improvement Lead,
More informationThe use of Chromatography Membranes for the development and production of biopharmaceuticals.
The use of Chromatography Membranes for the development and production of biopharmaceuticals. Dr. Juan Pablo Acosta Martinez Project Manager. Virus and Contaminant Clearance Sartorius Stedim Biotech Agenda
More informationTOYOPEARL GigaCap Series
TOYOPEARL GigaCap Series INTRODUCTION Ion Exchange Chromatography (IEC) is one of the most frequently used chromatographic modes for the separation and purification of biomolecules. Compared with other
More informationEvaluation of novel CEX resin for continous processing of MAb purification
Engineering Conferences International ECI Digital Archives Integrated Continuous Biomanufacturing II Proceedings Fall 11-2-2015 Evaluation of novel CEX resin for continous processing of MAb purification
More informationWorkBeads Protein A INSTRUCTIONS IN
WorkBeads Protein A INSTRUCTIONS IN 40 605 010 WorkBeads Protein A resin is designed for the purification of monoclonal and polyclonal antibodies using affinity chromatography. For small scale purification
More information3. Close the bottom end of the column and apply the packing device on top. Pump water through the upper adaptor to remove air.
INSTRUCTIONS FOR USE WorkBeads Protein A Product name Pack size Article number WorkBeads Protein A Bulk Media 1.5 ml 40605001 Bulk Media 5 ml 40605002 Bulk Media 10 ml 40605003 Bulk Media 100 ml 40605004
More informationThe monoclonal antibody (MAb) market
Reimagining Capacity for Today s Purification of Monoclonal Antibodies Jonathan Royce The monoclonal antibody (MAb) market has grown over the past decade to be about half of the biomanufacturing market
More informationEmerging and Enabling Technologies in Membrane Separations
Emerging and Enabling Technologies in Membrane Separations Andrew L. Zydney Distinguished Professor of Chemical Engineering The Pennsylvania State University 2 nd International Symposium on Continuous
More informationBuffer Make up Comparison: Continuous Inline versus Cycling Batch. Greg Lepak Craig Sandstrom
Buffer Make up Comparison: Continuous Inline versus Cycling Batch Greg Lepak Craig Sandstrom Agenda Sample Projects Model Process & Key Assumptions Buffer Estimates Equipment Flow Diagram Comparisons Process
More informationKeeping ahead in biopharmaceutical manufacturing
Keeping ahead in biopharmaceutical manufacturing Bioprocessing Network Annual Conference 2009 1 st October 2009 Dr Owen Tatford Process Development Manager May 2009 Biostate Process Overview 1 Introduction
More informationNext-generation, high-capacity, alkalistable
Evaluation of a Next-Generation Protein A Chromatography Resin for the Purification of Monoclonal Antibodies Bryan Dransart, April Wheeler, Tony Hong, Chi Tran, Rafael Abalos, Andrew Quezada, ShiYu Wang,
More informationMabSelect. GE Healthcare. Characteristics
GE Healthcare Data File 18-1149-94 AE Affinity chromatography is a BioProcess affinity medium for capturing monoclonal antibodies from large volumes of feed by packed bed chromatography. offers the following
More informationFast Trak Services: a collaborative project to accelerate downstream biosimilar process development
GE Healthcare Fast Trak Services: a collaborative project to accelerate downstream biosimilar process development A case study Case study, 2924332 AA Fast Trak Services A collaborative project to accelerate
More informationMabSelect Xtra. GE Healthcare. Recombinant protein A-based, high-capacity affinity medium. Medium characteristics Description
GE Healthcare Data File 11-11-7 AB Affinity chromatography MabSelect Xtra Recombinant protein A-based, high-capacity affinity medium Many disorders that are treated with monoclonal antibodies, e.g. cancer
More informationMabSelect Xtra * GE Healthcare Life Sciences. Medium characteristics Description. MabSelect family
GE Healthcare Life Sciences Data file 11-11-7 AC Affinity chromatography MabSelect Xtra * MabSelect Xtra is a recombinant protein A-based affinity medium engineered to give an exceptionally high dynamic
More informationDynamic High Capacity Mustang Q Membrane Units for Scaleable Anion Exchange Chromatography Purification of Adenoviral Vectors
Contact Us: www.pall.com/contact Dynamic High Capacity Mustang Q Membrane Units for Scaleable Anion Exchange Chromatography Purification of Adenoviral Vectors Dynamic High Capacity Mustang Q Membrane Units
More informationUpstream mammalian cell processing challenges and prospects
BioProcess International Berlin, April 11-14, 2005 Upstream mammalian cell processing challenges and prospects John Birch Lonza Significance of Mammalian Cell Processes Commercial significance of biopharmaceutical
More informationPolishing of monoclonal antibodies using Capto S ImpAct
Application note 29-83-27 AA Ion exchange chromatography Polishing of monoclonal antibodies using Capto S ImpAct Capto S ImpAct chromatography medium (resin) is a strong cation exchanger (CIEX). The medium
More informationFast Trak Services: Long-term collaboration supports speed to market in single-use biomanufacturing
GE Healthcare Fast Trak Services: Long-term collaboration supports speed to market in single-use biomanufacturing A case study Fast Trak Services Long-term collaboration supports speed to market in single-use
More informationAn effective platform for purification of IgM monoclonal antibodies using Hydroxyapatite
An effective platform for purification of IgM monoclonal antibodies using Hydroxyapatite Frank Hensel, Patrys, GmbH Pete Gagnon, Validated Biosystems 5th International Conference on Hydroxyapatite and
More informationBuilding the Vaccine Manufacturing Platforms of the Future: Disposable Manufacturing. Mats Lundgren, PhD GE Healthcare Life Sciences
Building the Vaccine Manufacturing Platforms of the Future: Disposable Manufacturing Mats Lundgren, PhD GE Healthcare Life Sciences Introduction 2 Why use disposables in vaccine production? Vaccines often
More informationOperational & Economic Evaluation of Integrated Continuous Biomanufacturing Strategies for Clinical & Commercial mab Production
UCL Decisional Tools Research Operational & Economic Evaluation of Integrated Continuous Biomanufacturing Strategies for Clinical & Commercial mab Production Suzanne Farid PhD CEng FIChemE Reader (Associate
More informationMimetic Blue Affinity Adsorbents Mimetic Blue 1 P6XL, Mimetic Blue SA P6XL Mimetic Blue SA HL P6XL, Mimetic Blue ELISA Kit
Mimetic Blue Affinity Adsorbents Mimetic Blue 1 P6XL, Mimetic Blue SA P6XL Mimetic Blue SA HL P6XL, Mimetic Blue ELISA Kit WWW.PROMETICBIOSCIENCES.COM/PRODUCT DATASHEET Mimetic Blue affinity chromatography
More informationProductivity improvements in the capture and initial purification of monoclonal antibodies
Productivity improvements in the capture and initial purification of monoclonal antibodies Pete Gagnon, Validated Biosystems Inc. Richard Richieri, Avid Bioservices, Inc. 2 nd Wilbio Conference on Purification
More informationMulti-column Continuous Capture Chromatography New data confirming significant savings and de-bottlenecking opportunities
Multi-column Continuous Capture Chromatography New data confirming significant savings and de-bottlenecking opportunities Dr.-Ing. Kathleen Mihlbachler, LEWA Bioprocess Repligen Seminar: Advances in Bioprocessing,
More informationThe above media is designed to capture antibodies or other molecules of similar size.
Data sheet SepFast TM Capture Q (400, 500, 600) SepFast TM Capture DEAE (400, 500, 600) SepFast TM Capture S (400, 500, 600) SepFast TM Capture CM (400, 500, 600) 1. Introduction SepFast Capture Q, SepFast
More informationDeveloping an Appropriate Design Space Strategy to Mitigate Variability in Downstream Processing Operations
1 Developing an Appropriate Design Space Strategy to Mitigate Variability in Downstream Processing Operations Justin McCue Biogen Idec Corporation September, 2010 1 2 Overview Chromatography column scale
More informationImproving Bioprocessing Productivity Through the Application of Single-Use Protein A Columns
Improving Bioprocessing Productivity Through the Application of Single-Use Protein A Columns By K. John Morrow, Jr. Ph.D. In the last two decades, the bioprocessing industry has confronted the demands
More informationFast Trak Services: Ongoing collaboration aims to accelerate biosimilar approval in China
GE Healthcare Fast Trak Services: Ongoing collaboration aims to accelerate biosimilar approval in China A case study Fast Trak Services Ongoing collaboration aims to accelerate biosimilar approval in China
More informationPhenyl Membrane Adsorber for Bioprocessing
Phenyl Membrane Adsorber for Bioprocessing Sartobind Hydrophobic Interaction Membrane Chromatography The low substitution of the phenyl ligand on the membrane allows for mild elution of biomolecules such
More informationQ and S HyperCel Sorbents
Product Note USD 9 () Q and S HyperCel Sorbents High Productivity Ion Exchangers for Protein Capture and Separations Product Description and Application Overview Introduction Q and S HyperCel sorbents
More informationConvenient Purification of Monoclonal Antibodies using HiTrap rprotein A FF
GE Healthcare Convenient Purification of Monoclonal Antibodies using HiTrap rprotein A FF M. Carlsson, A. Heijbel, and A-C. Häggqvist GE Healthcare AB, Björkgatan 3, SE-751 84 Uppsala, Sweden Abstract
More informationHyperCel STAR AX Ion Exchange Sorbent
USD 2831(2) HyperCel STAR AX Ion Exchange Sorbent Salt Tolerant Advanced Recovery Anion Exchange Chromatography Sorbent An industry-scalable anion exchange chromatography sorbent designed for high productivity
More informationAdsorptive and Mechanical Mechanisms of Fluid Purification Using Charge Modified Depth Filtration Media. Dr. Robert Conway, Ph.D.
Adsorptive and Mechanical Mechanisms of Fluid Purification Using Charge Modified Depth Filtration Media Dr. Robert Conway, Ph.D. Depth Filter Cartridge Construction Zeta Plus Media Materials of Construction
More informationPhenyl Membrane Adsorber for Bioprocessing
Phenyl Membrane Adsorber for Bioprocessing Sartobind Hydrophobic Interaction Membrane Chromatography The low substitution of the phenyl ligand on the membrane allows for mild elution of biomolecules such
More informationPhenyl Sepharose High Performance Butyl Sepharose High Performance
Instructions 71-7129-00 AF Hydrophobic interaction Phenyl Sepharose High Performance Butyl Sepharose High Performance Phenyl Sepharose TM High Performance and Butyl Sepharose High Performance are members
More informationMabSelect SuRe pcc. Medium characteristics. GE Healthcare. Affinity chromatography. Optimized for continuous chromatography applications
GE Healthcare Affinity chromatography MabSelect SuRe pcc MabSelect SuRe pcc affinity chromatography medium (resin) offers exceptional capacity at short residence time, making it well-suited for applications
More informationTools and solutions for separation of charged mab variants
GE Healthcare Tools and solutions for separation of charged mab variants A biosimilar is an almost identical version of an originator product, but to attain regulatory approval, a comparable quality to
More informationThe Use of Disposable and Alternative Purification Technologies for Biopharmaceuticals
The Use of Disposable and Alternative Purification Technologies for Biopharmaceuticals Tom Ransohoff BioProcess Technology Consultants July 22, 2005 IIR Biopharmaceutical Production Conference Presentation
More informationImproving Downstream Manufacturing Productivity with Pre-Packed Chromatography Columns
Improving Downstream Manufacturing Productivity with Pre-Packed Chromatography Columns Michael Dittmer MedImmune, BioProcess Engineering BPI West, San Francisco, CA March 2 nd, 2017 Outline Motivation
More informationHiScreen prepacked columns
GE Healthcare Life Sciences Data file 28-935-81 AF Process development HiScreen prepacked columns HiScreen columns are part of the process development platform available from GE Healthcare (Fig 1). The
More informationFuture biologics manufacturing
Future biologics manufacturing Process integration with single-use technology Dr. Günter Jagschies Senior Director, Strategic Customer Relations GE Healthcare Life Sciences Uppsala, Sweden Mammalian Cell
More informationG-Sep Ion Exchange Agarose Fast Flow
622PR-01 G-Biosciences 1-800-628-7730 1-314-991-6034 technical@gbiosciences.com A Geno Technology, Inc. (USA) brand name G-Sep Ion Exchange Agarose Fast Flow CM, DEAE, Q & SP Agarose Fast Flow (Cat. #
More informationG-Sep Ion Exchange Agarose Fast Flow
622PR-01 G-Biosciences 1-800-628-7730 1-314-991-6034 technical@gbiosciences.com A Geno Technology, Inc. (USA) brand name G-Sep Ion Exchange Agarose Fast Flow CM, DEAE, Q & SP Agarose Fast Flow (Cat. #
More informationCapacity and performance of MabSelect PrismA protein A chromatography resin
Capacity and performance of protein A chromatography resin is a protein A resin of which both the ligand and the base matrix have been optimized. The resin exhibits improved capacity over its predecessor
More informationPresented at the ECI Conference on Integrated Continuous Biomanufacturing Castelldefels, Spain, October 21, 2013
Continuous Antibody Capture with Protein A Countercurrent Tangential Chromatography: A New Column-Free Approach for Antibody Purification Andrew L. Zydney Department Head and Walter L. Robb Family Chair
More informationOperating Instructions Heparin Mimetic Affinity
DexS Cellufine MAX DexS is a new chromatography resin incorporating Dextran sulfate polymer surface modification. This non-animal derived pseudo affinity ligand can be used instead of immobilized Heparin
More informationTraining Program 2019
www.bcc.ch info@bcc.ch Biofactory Competence Center SA Passage du Cardinal 13b 1700 Fribourg (CH) Training Program 2019 Training is delivered by subject matter experts from both academia and those with
More informationHiTrap convenient protein purification
GE Healthcare Life Sciences HiTrap convenient protein purification Column Guide Ion Exchange Chromatography (IEX) IEX separates proteins with differences in charge. The separation is based on the reversible
More informationProtein A Mag Sepharose Xtra Protein G Mag Sepharose Xtra
GE Healthcare Data file 28-9768-1 AA Protein sample preparation Protein A Mag Sepharose Xtra Xtra products are magnetic beads designed for efficient, high capacity small-scale purification/screening of
More informationNew technologies in biopharmaceutical processes BioTech Vaccines Plasma
New technologies in biopharmaceutical processes BioTech Vaccines Plasma Dominik Arnold dominik_arnold@pall.com Challenges in Down Stream Processing Higher. Titers >4 g/l Yield > 90% Protein concentration
More informationProSep Ultra Plus Chromatography Media
Data Sheet Data Sheet ProSep Ultra Plus Chromatography Media The highest dynamic binding capacity protein A affinity chromatography media, designed for cost effective, large-scale purification of today
More informationGORE. Protein Capture Devices. Operating Instructions Contents. Product Description Device Characteristics... 2 General Handling...
GORE Protein Capture Devices Operating Instructions Contents Product Description............................... 2 Device Characteristics............................. 2 General Handling................................
More informationSartobind IEX nano 3 ml
Operating Instructions Sartobind IEX nano 3 ml A Separation Technology Based on Macroporous Membranes, 8 mm Bed Height 85032-536-01 Information Please read the operation instruction carefully before using
More informationPerformance of the AbSolute High Cap resin in the Nimotuzumab capture step
Research Article Journal of Biotechnology and Bioengineering Volume 1 Issue 1 Open Access Performance of the AbSolute High Cap resin in the Nimotuzumab capture step Martinez Rosario 1*, Ruland Yvan 2,
More informationHyperCel STAR AX Ion Exchange Sorbent
USD 28312a HyperCel STAR AX Ion Exchange Sorbent Salt Tolerant Advanced Recovery Anion Exchange Chromatography Sorbent An industry-scalable anion exchange chromatography sorbent designed for high productivity
More informationEconomic Impact of Single-Use Bioreactors
Economic Impact of Single-Use Bioreactors Rick Stock 2012 BIO International Convention BioProcess Theater Presentation Upstream Processing Boston, MA June 19th, 2012 BioProcess Technology Consultants www.bptc.com
More informationRecent Developments & Future Directions in the Production of Monoclonal Antibodies. Rob Noel Plasma Product Biotechnology Conference 2009, Menorca
Recent Developments & Future Directions in the Production of Monoclonal Antibodies Rob Noel Plasma Product Biotechnology Conference 2009, Menorca Forecast sales by molecule type ($m), 2006 12 600,000 Pharmaceuticals
More informationEnhancing Upstream and Downstream Process Methods Through Implementation of Single-Use Technologies. 06 February 2018
Enhancing Upstream and Downstream Process Methods Through Implementation of Single-Use Technologies 06 February 2018 Overview Single-use technology (SUT) is a rapidly evolving technology that focuses on
More informationChallenges in Scaling Up Newly Developed Microbial Manufacturing Processes
Challenges in Scaling Up Newly Developed Microbial Manufacturing Processes Susan Dana Jones, Ph.D. BioProcess Technology Consultants BIO Process Zone Theater June 19, 2008 Microbial Process Development
More informationProtein A Ceramic HyperD F Affinity Chromatography Sorbent
PRODUCT NOTE BIOSEPRA Protein A Ceramic HYPERD F Protein A Ceramic HyperD F Affinity Chromatography Sorbent Ideal for large-scale antibody purification. High binding capacity for human and murine IgGs.
More informationCellufine MAX Q-r, Cellufine MAX Q-h
Operating Instructions Ion exchange Chromatography Media Cellufine MAX Q-r, Cellufine MAX Q-h Description Cellufine MAX is the new name of 2 nd generation Cellufine chromatography media. Cellufine MAX
More informationRhinophase -AB, Zirconia-based Monoclonal Antibody Purification System
Rhinophase -AB, Zirconia-based Monoclonal Antibody Purification System Welcome to the sixth issue of ZirChrom's electronic newsletter. This newsletter introduces a biocompatible stationary phase useful
More informationChapter 1 Principles of ion exchange
Chapter 1 Principles of ion exchange This chapter provides a general introduction to the theoretical principles that underlie every ion exchange separation. An understanding of these principles will enable
More informationThe Eshmuno Chromatography Family of Resins
The Eshmuno Chromatography Family of Resins The perfect accessory for highly productive downstream purification EMD Millipore is a division of Merck KGaA, Damstadt, Germany Introduction For over 300 years,
More informationProtein A Resins. Modern, Advanced High-Flow, Highly Cross-Linked Agarose Resins For Improved Process Economics.
Protein A Resins Modern, Advanced High-Flow, Highly Cross-Linked Agarose Resins For Improved Process Economics. www.purolite.com/life-sciences Why Purolite? For over 35 years, Purolite has supplied specialty
More informationCapto S, Capto Q, and Capto DEAE
GE Healthcare Life Sciences Data file --76 AG Ion exchange chromatography Capto S, Capto Q, and Capto DEAE, Capto Q and Capto DEAE are, respectively, strong cation, strong anion and weak anion exchange
More informationBIOSEPRA MBI HYPERCEL. Mixed-mode sorbent for direct capture of antibodies.
MBI HYPERCEL Mixed-mode sorbent for direct capture of antibodies. Designed for direct capture of monoclonal and polyclonal. Alternative to Protein A sorbents. Complement to Hydrophobic Charge Induction
More informationPrinciples, Practice and Guided Evolution of Biologics Manufacturing Platforms
Principles, Practice and Guided Evolution of Biologics Manufacturing Platforms David Beattie R&D Director, Biotech Process Solutions EMD Millipore, a division of Merck KGaA CMC Forum Europe 2011 Barcelona
More informationA novel multimodal anion exchanger designed for monoclonal antibody purification
A novel multimodal anion exchanger designed for monoclonal antibody purification IBC s 18th International, Antibody Development &Production February-March, 2007 Hans J Johansson, Anders Ljunglöf, Kjell
More informationDriving Value through Innovation in Biotech Manufacturing. Agenda
Driving Value through Innovation in Biotech Manufacturing Jorg Thommes, PhD Senior Vice President Operations Technology and Innovation Biogen 7 October 2015 Agenda Biopharma Legacy, Trends, & Challenges
More informationMAbPurix TM Protein A Affinity Chromatography Resin media and column
MAbPurix TM Protein A Affinity Chromatography Resin media and column Excellent Choice for Monoclonal Antibody Purification High Quality & Performance Significant Cost Saving Excellent technical support
More informationSubject Index. chromatography step, 125-
A Alert limits, description, 70 Aluminum hydroxide based vaccine manufacture, start up and validation of sterile formulation and filling processes, 144-168 Anion-exchange chromatography step for clinical-grade
More informationDevelopment from Bench to Clinic
Accelerating Novel Vaccine Development from Bench to Clinic Roger Lias. Ph.D. President Eden Biodesign, Inc Questions Questions are encouraged and can be asked by sending an email to: edenbiodesign@propelmg.com
More informationTransferring a process to a contract
Reprinted from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE July/August 2010, Vol. 30 No. 4 www.ispe.org Copyright ISPE 2010 This article presents a process transfer case study and the significance
More informationContinuous mab Purification Process: Design Features and Practical Considerations
Continuous mab Purification Process: Design Features and Practical Considerations Joanna Pezzini CASSS DC Area Discussion Group Meeting December 7, 2017 Outline Continuous Process Overview Continuous Technologies
More informationPerfusion and Beyond The XCell TM ATF System
Perfusion and Beyond The XCell TM ATF System Earl Pineda Field Application Scientist Web ads May 9, 2018 Inspiring advances in bioprocessing since 1985 Repligen Corporation: one of the fastest-growing
More informationCapto adhere ImpRes. GE Healthcare Life Sciences. Polishing medium for MAb platform processes
GE Healthcare Life Sciences Data file 29-344-97 AA Multimodal chromatography Capto adhere ImpRes Capto adhere ImpRes is a BioProcess chromatography medium (resin) for high-resolution polishing of monoclonal
More informationHiScreen MabSelect SuRe HiScreen MabSelect SuRe LX HiScreen MabSelect HiScreen MabSelect Xtra
GE Healthcare Life Sciences Instructions 28-9339-49 AD HiScreen affinity columns HiScreen MabSelect SuRe HiScreen MabSelect SuRe LX HiScreen MabSelect HiScreen MabSelect Xtra Introduction HiScreen MabSelect
More informationCapto * Blue and Capto Blue (high sub)
GE Healthcare Life Sciences Data file 28-9369-6 AC Affinity chromatography Capto * Blue and (high sub) and (high sub) are affinity chromatography media (resins) for the capture of human serum albumin,
More informationGE Healthcare. Purification of monoclonal antibodies using modern chromatography media and membranes
GE Healthcare Purification of monoclonal antibodies using modern chromatography media and membranes Purification of monoclonal antibodies using modern chromatography media and membranes The use of monoclonal
More informationSubject Index. See for options on how to legitimately share published articles.
Downloaded via 148.251.232.83 on March 27, 2019 at 03:59:27 (UTC). See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles. A Alert limits, description, 70
More informationMonoclonal Antibody Purification and Technology for Improving Virus Clearance
Monoclonal Antibody Purification and Technology for Improving Virus Clearance BioProcessing Network Annual Conference Brisbane, September 2009 Germano Coppola Technology Transfer Manager CSL Limited Outline
More information1. Bloomsbury BBSRC Centre for Structural Biology, Birkbeck College and University College London.
Purification/Polishing of His-tagged proteins - Application of Centrifugal Vivapure Ion-exchange Membrane Devices to the Purification/Polishing of Histagged Background Multi-milligram quantities of highly
More informationA complete single-use manufacturing process of monoclonal antibodies: a case study
A complete single-use manufacturing process of monoclonal antibodies: a case study Jakob Liderfelt, Janne Simola, Annika Forss, Gustav Rodrigo, Karin Torstensson, Tomas Björkman, Kjell Eriksson, Hans J
More informationRECENT IMPROVEMENTS TO LONZA S GLUTAMINE SYNTHETASE (GS) GENE EXPRESSION SYSTEM. Dr Robert Gay
RECENT IMPROVEMENTS TO LONZA S GLUTAMINE SYNTHETASE (GS) GENE EXPRESSION SYSTEM Dr Robert Gay Lonza Biologics plc, 2004 The Challenge of the MAb Market Global market for Monoclonal Antibody Therapeutics
More informationChromatography Guide. Modern, Advanced High-Flow, Highly Cross-Linked Agarose Resins For Improved Process Economics.
Chromatography Guide Modern, Advanced High-Flow, Highly Cross-Linked Agarose Resins For Improved Process Economics. www.purolite.com/life-sciences Why Purolite? For over 35 years, Purolite has supplied
More informationDesigning Next Generation Chromatography Media for Modern High-Throughput Plasma Processes. Mats Gruvegård PPB 09 Menorca, Spain
Designing Next Generation Chromatography Media for Modern High-Throughput Plasma Processes Mats Gruvegård PPB 09 Menorca, Spain utline Introduction Process needs Performance Designing a base matrix Screening
More informationThe above media is designed to purify antibodies from aggregates and other impurities.
Data sheet SepFast TM Purifier Q (400, 500, 600) SepFast TM Purifier DEAE (400, 500, 600) SepFast TM Purifier S (400, 500, 600) SepFast TM Purifier CM (400, 500, 600) 1. Introduction SepFast Purifier Q,
More information